LSE:AVCT (Avacta Group Plc)

About AVCT

Avacta is an early-stage biotech firm specialising in the fields of diagnostics and therapeutics. Its diagnostics division created a proprietary platform called Affimer. It consists of a portfolio of reagent proteins that can be used to detect specific infections within a given sample. Traditionally this process is achieved using antibodies. However, manufacturing antibodies is a complex, time-consuming process that Affimer reagents don’t have to go through. In 2020, Avacta leveraged its Affimer platform to create Covid-19 lateral flow tests. This was the catalyst behind the AVCT share price spike that year. On the therapeutics side of the business, the company is currently testing its flagship AVA6000 chemotherapy drug in clinical trials. This treatment is being developed with the group’s second chemical platform called pre|CISION. Unlike existing chemotherapy treatments, AVA6000 is highly targeted, resulting in less healthy cells being caught in the crossfire, and reducing the severity of side effects.
  • Frequently Asked Questions

    Avacta was listed on the London Stock Exchange Alternative Investment Market in October 2003 through a reverse takeover. The split-adjusted floating price was 5,250p.

    No. According to the 2020 annual report, Avacta does not pay dividends to shareholders, nor has it proposed to do so in the future.

    Avacta Group Plc (LSE: AVCT) Latest News

    Illustration of flames over a black background
    Investing Articles

    Down 63% in 2024, what’s going on with the Avacta (AVCT) share price?

    2024 has been a difficult year for many companies in the biotechnology sector, with the AVCT share price down heavily.…

    Read more »

    A GlaxoSmithKline scientist uses a microscope
    Investing Articles

    If I’d invested £1,000 in Avacta shares 5 years ago, here’s how much I’d have now

    Avacta shares have risen substantially over the past five years. Should I buy the biotech stock today in case it…

    Read more »

    A senior woman sits up on the exam table at a doctors appointment. She is dressed casually in a blue sweater and has a smile on her face as she glances at the doctor. Her female doctor is wearing a white lab coat and seated in front of her as she takes notes on a tablet.
    Investing Articles

    Avacta shares quadrupled in five years! Am I too late to buy?

    Christopher Ruane thinks the incredible run of Avacta shares over the past few years may have room left to run.…

    Read more »

    Investing Articles

    Is the Avacta share price dip a buying opportunity?

    I would buy Avacta at its current share price if I was comfortable with the risk inherent in its developmental…

    Read more »

    Engineer Project Manager Talks With Scientist working on Computer
    Investing Articles

    Is the Avacta share price about to rocket in 2023?

    The Avacta share price is up an incredible 560% in just three years. But could this exciting biotech be about…

    Read more »

    Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
    Investing Articles

    Can the Avacta share price make me rich?

    Is the Avacta share price about to take off again and can it make me rich if I invest now?…

    Read more »

    Engineer Project Manager Talks With Scientist working on Computer
    Investing Articles

    Up 173%, can Avacta shares continue this incredible run?  

    In the last few months, Avacta shares have jumped significantly. But does this warrant an investment or is it just…

    Read more »

    Engineer Project Manager Talks With Scientist working on Computer with the text “Investing in Biotech: Top UK Biotech Stocks in 2022” and The Motley Fool jester cap logo
    Page

    Investing in Biotech: Top UK Biotech Stocks of 2024

    Uncover the top UK biotech stocks & shares leading the charge in what could be a multi-trillion-dollar investment opportunity for…

    Read more »

    Investing Articles

    What’s next for the Avacta share price?

    The Avacta share price has crashed by almost 80%! But is this a buying opportunity for patient investors? Zaven Boyrazian…

    Read more »

    Investing Articles

    The Avacta share price: buy or avoid like the plague?

    With two revolutionary cancer treatments, is Avacta becoming increasingly attractive?

    Read more »

    Investing Articles

    What’s going on with the Avacta share price?

    This Fool explains why he thinks the Avacta share price has been underperforming, and the catalyst that could cause a…

    Read more »

    Investing Articles

    The Avacta (AVCT) share price has halved since May. Can it make a comeback?

    The Avacta (LON:AVCT) share price continues to tumble on rising costs, but can it make a comeback? Zaven Boyrazian investigates.

    Read more »